Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMN 333
- Development stage
- Phase 3
- Lead developer
- BioMarin Pharmaceutical
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
BMN 333 is a long-acting C-type natriuretic peptide (CNP) being developed by BioMarin Pharmaceutical for the treatment of skeletal growth disorders, primarily achondroplasia and hypochondroplasia. It is designed to build upon BioMarin's existing drug VOXZOGO, offering potentially greater efficacy through sustained CNP exposure. The drug leverages similar chemistry from other approved drugs to prolong half-life and potentially enable weekly dosing instead of daily administration required for VOXZOGO.
- Other names
- Long acting C-type natriuretic peptideLong acting CNP - BioMarin Pharmaceuticals
02
Targets
NPR2 (C-type Natriuretic Peptide Receptor B)
Beyond the preview
Go deeper on BMN 333.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMN 333.